Seeking Alpha

Prolor Biotech (PBTH) is due to present preclinical data tomorrow providing further evidence...

Prolor Biotech (PBTH) is due to present preclinical data tomorrow providing further evidence that its Factor VIIa-CTP hemophilia therapy can be administered with an injection as well as intravenously. Providing the clotting agent via an injection would facilitate its prophylactic use by patients as a way to prevent bleeding rather than just for when a bleeding episode occurs. Prolor Biotech hopes to start two clinical trials for the treatment next year. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)